Will Hulme
Statistical epidemiologist
I am a statistical epidemiologist at the Bennett Institute for Applied Data Science, interested in improving how routinely-collected health data can be used for prediction and inference, and improving research transparency and reusability in sensitive data settings.
I lead the Bennett Institute’s Epidemiology team, and co-lead the OpenSAFELY COVID-19 Vaccine Effectiveness Working Group.
My recent work has focused on target trial emulation and its use for vaccine effectiveness estimation.
Papers by Will Hulme
- Comparative safety and effectiveness of Pfizer BA.4-5 versus Sanofi during the spring 2023 COVID-19 booster vaccination programme in England: a matched cohort study in OpenSAFELY-TPP
- Changes in opioid prescribing during the COVID-19 pandemic in England: cohort study of 20 million patients in OpenSAFELY-TPP
- OpenSAFELY: Measuring BMI in 22 million patients in England
- OpenSAFELY: a platform for analysing electronic health records designed for reproducible research
- Trends in inequalities in avoidable hospitalisations across the COVID-19 pandemic: a cohort study of 23.5 million people in England
- Consistency, completeness and external validity of ethnicity recording in NHS primary care records: a cohort study in 25 million patients’ records at source using OpenSAFELY
- Effect of the 2022 COVID-19 booster vaccination campaign in 50 year olds in England: regression discontinuity analysis in OpenSAFELY
- Challenges in Estimating the Effectiveness of 2 Doses of COVID-19 Vaccine Beyond 6 Months in England
- The impact of COVID-19 on medication reviews in English primary care. An OpenSAFELY-TPP analysis of 20 million adult electronic health records.
- The impact of the COVID-19 pandemic on Antipsychotic Prescribing
- Eleven key measures for monitoring general practice clinical activity during COVID-19: A retrospective cohort study using 48 million adults’ primary care records in England through OpenSAFELY
- DMARD monitoring during the COVID-19 pandemic
- Changes in medication safety indicators in England throughout the covid-19 pandemic using OpenSAFELY: population based, retrospective cohort study of 57 million patients using federated analytics
- Challenges in Estimating the Effectiveness of COVID-19 Vaccination Using Observational Data
- Changes in COVID-19-related mortality across key demographic and clinical subgroups in England from 2020 to 2022: a retrospective cohort study using the OpenSAFELY platform
- Comparative effectiveness of BNT162b2 versus mRNA-1273 covid-19 vaccine boosting in England: matched cohort study in OpenSAFELY-TPP
- First dose COVID-19 vaccine coverage amongst adolescents and children in England: an analysis of 3.21 million patients' primary care records in situ using OpenSAFELY
- Severity of Severe Acute Respiratory System Coronavirus 2 (SARS-CoV-2) Alpha Variant (B.1.1.7) in England